Abstract: An improved dietary and/or therapeutic supplement composition comprising a quantity of a dietary and/or therapeutic supplement agent having a pH that upon ingestion with food or a beverage would limit the effectiveness of the agent and a sufficient amount of an alkaline electrolyte additive is provided in combination with the agent to raise the pH of the composition to a level of from about 8 to about 12.5 to increase the effectiveness and functional utilization of the agent while the composition is in the person's stomach. In a preferred composition, the electrolyte additive is selected from the group consisting of calcium, magnesium and potassium electrolytes. The supplement composition may be in the form of tablet, capsule, powder or liquid forms. The supplement composition is designed to provide for optimum utilization of a dietary and/or therapeutic supplement agent when taken orally with food or a beverage.
Abstract: An adjuvant composition is provided which comprises: (a) at least one water-soluble electrolyte; (b) at least one electrolyte-tolerant surfactant; (c) antifoam component which is at least one mixture selected from the group consisting of (1) at least one branched silicone resin (i), at least one silicone fluid (ii), at least one particulate metal oxide (iii) and, optionally, at least one catalyst (iv) for catalyzing the condensation of siloxy groups, (2) the equilibration reaction product of mixture (1), and (3) mixture (1) in which at least a portion of particulate metal oxide (iii) is pre-hydrophobized; (d) optionally, at least one additional bioinert material; and, (e) water.
Type:
Grant
Filed:
May 9, 2011
Date of Patent:
October 8, 2013
Assignee:
Momentive Performance Materials Inc.
Inventors:
William L Brown, Kalman Koczo, George A Policello
Abstract: A pharmaceutical kit for treating neuronal damages is disclosed. The pharmaceutical composition of the present invention comprises: a first pharmaceutical composition comprising a first effective amount of a Mg2+-containing compound; and a second pharmaceutical composition comprising a second effective amount of a COX-2 inhibitor.
Abstract: Disclosed herein are compositions and methods for treating a variety of mood and behavioral disorders, including attention deficit hyperactivity disorder (ADHD), anxiety, depression, memory loss, as well as other conditions. Also disclosed herein are methods for diagnosing certain conditions, such as ADHD, using these compositions.
Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
Type:
Grant
Filed:
October 22, 2009
Date of Patent:
October 1, 2013
Assignee:
MPEX Pharmaceuticals, Inc.
Inventors:
Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.
Type:
Grant
Filed:
May 21, 2009
Date of Patent:
September 17, 2013
Assignee:
Argent Development Group, LLC
Inventors:
John C. Morrison, Kenneth R. Greathouse
Abstract: A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P2O5, SiO2, and B2O3; at least about 25 wt % of the fibers have a diameter between about 200 nm and about 4000 nm, and a length:width aspect ratio of at least about 10. In another form, the glasses are in the form of particles in an ointment or cream applied to a wound. In yet other forms the glasses are employed as fibers formed into sutures for closing a wound, or as particles in a surgical glue for closing a wound.
Type:
Grant
Filed:
April 9, 2012
Date of Patent:
September 17, 2013
Assignee:
The Curators of the University of Missouri
Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.
Type:
Grant
Filed:
November 7, 2011
Date of Patent:
September 17, 2013
Assignee:
Argent Development Group, LLC
Inventors:
John C. Morrison, Kenneth R. Greathouse
Abstract: A magnesium-based system suitable for use in skincare comprises (a) a first magnesium source in the form of a progressive-release oral tablet exhibiting in vitro, after 2h in 0.1N HCl medium, a rate of dissolution (?) of the magnesium contained therein of less than or equal to 60% by weight relative to the total weight of the Mg provided by the first magnesium source, and (b) a second magnesium source in a topical preparation. A method for treating skin for stress, fatigue or skin barrier deficiencies, as well as for stratum corneum hydration, includes orally and topically administering magnesium sources (a) and (b), respectively.
Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
Type:
Grant
Filed:
October 22, 2009
Date of Patent:
September 3, 2013
Assignee:
MPEX Pharmaceuticals, Inc.
Inventors:
Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
Type:
Grant
Filed:
October 22, 2009
Date of Patent:
September 3, 2013
Assignee:
MPEX Pharmaceuticals, Inc.
Inventors:
Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
Abstract: Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels.
Type:
Application
Filed:
April 9, 2013
Publication date:
August 29, 2013
Applicant:
PHARMALYTE SOLUTIONS, LLC
Inventors:
Stephen F. Brandon, Feng Zhang, Stuart Schoenherr
Abstract: The present invention provides geodate delivery vehicles and methods of manufacture and administration. A vehicle including a lipid monolayer disposed about a hydrophobic domain is disclosed, that can be part of an emulsion or other mixture, or further disposed in a lipid strata. A vehicle including a lipid strata disposed about a hydrophobic domain is also disclosed. The vehicle can be incorporated into a variety of medicinal, food preparations, and personal care products to deliver or stabilize a cargo moiety. Packaged delivery vehicles for later addition of cargo moieties are also contemplated.
Type:
Application
Filed:
April 1, 2013
Publication date:
August 29, 2013
Inventors:
Raphael J. Mannino, Sara L. Krause-Elsmore, Susan Gould-Fogerite, David Delmarre, Ruying Lu
Abstract: The invention relates to a novel two-phase preparation for use as a food supplement, dietary substance, and/or medicament. The medical use thereof for helping the immune system fight against viral diseases, especially herpes, is particularly preferred. Said preparation may have two different phases which may be used in a chronologically staggered manner, mutually blocking agents being in different phases and mutually boosting agents being in the same phase.
Abstract: The present invention relates to a method for reducing or eliminating loss of minerals from the enamel and dental hypersensitivity against temperature changes, in particular when caused by the bleaching of teeth with products containing hydrogen peroxide or other oxidizing agents. After the bleaching process the teeth are treated with a calcium hydroxide containing solution, and subsequently the teeth are treated with a fluoride solution.
Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.
Type:
Application
Filed:
March 15, 2013
Publication date:
August 8, 2013
Inventors:
Daniel Henry WYROBNIK, Isaac Harry Wyrobnik
Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.
Type:
Application
Filed:
March 15, 2013
Publication date:
August 8, 2013
Inventors:
Daniel Henry WYROBNIK, Isaac Harry Wyrobnik
Abstract: A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof.
Abstract: The present invention relates to compositions and methods for treating pain wherein the compositions comprise a combination of tramadol or a pharmaceutically acceptable salt thereof, magnesium or a pharmaceutically acceptable salt thereof; and gabapentin or pregabalin. The therapeutic combination can further contain capsaicin or an ester of capsaicin.
Abstract: The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking.
Abstract: The present invention concerns solid compressed oral pharmaceutical compositions comprising a mixture of at least two sulphate salts selected from the group consisting of sodium, potassium and magnesium for use, in particular, in cleansing the colon or treating faecal impaction, constipation, faecal retention, intestinal gas and cramping, or flatulence in a mammal. Methods of producing such compositions are also disclosed.
Type:
Application
Filed:
July 26, 2011
Publication date:
July 25, 2013
Applicant:
Norgine BV
Inventors:
Alasdair Cockett, Paul Pay, Guy Cameron Nash
Abstract: Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine.
Abstract: The present invention discloses pharmaceutical/nutritional compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical/nutritional compositions include at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery.
Abstract: Provided is a method that enables a calcium silicate-based material to be produced more efficiently. The method of producing a calcium silicate-based material comprises: (1) a step of obtaining a reaction product by reacting raw materials containing a calcium component, a silicon component and an aluminum component in an aqueous medium; and (2) a step of forming calcium silicate by subjecting the reaction product to hydrothermal treatment.
Abstract: A method of manufacturing a bone prosthetic material, includes by forming tricalcium phosphate (TCP) particle precursor particles; by performing preliminary sintering on the TCP precursor particles at a temperature in a first temperature range to produce TCP particles of diameters in a predetermined diameter range; by granulating the TCP particles to produce granulated bodies; and by performing sintering on the granulated bodies at a temperature in a second temperature range to generate sinter assemblies. The second temperature range is higher than the first temperature range. In the bone prosthetic material manufactured thus, a first space in a range of 100 to 400 ?m is formed between adjacent two of a plurality of sintered assemblies. Each of the plurality of sintered assemblies includes tricalcium phosphate (TCP) particles which are subjected to sintering, and a second space in a range of 5 to 100 ?m is formed between adjacent two of the TCP particles. The second space communicates with the first space.
Abstract: The present invention relates to effervescent formulations comprising genistein with an average particle size (d50) in the range of 1 to 300 ?m as active agent. The present invention also relates to pharmaceutical formulations with high bioavailability comprising calcium, genistein and vitamin D in order to be used in prophylaxis and treatment of osteoporosis and related diseases.
Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
Abstract: The invention relates to a medicament, the active principle of which is a leucine and, for example, a N-ACETYL-DL-LEUCINE. It can be applied to the prevention and/or treatment of eye diseases or disorders and especially of hereditary dystrophies of the retina, glaucomatous neuropathy, glaucoma, macular degeneration, myopia, presbyopia, hypermetropia, astigmatism, all the ophtalmologic diseases or disorders inducing a decrease of visual function and/or age-related physiological vision decline.
Abstract: Nutritional compositions having the potential to reduce metabolic acid load and methods of making and using the nutritional compositions are provided. In an embodiment, the present disclosure provides methods of selecting and administering nutritional compositions to patients. The methods may include modifications to calculating a metabolic acid potential of a nutritional composition, calculating a base content of a nutritional composition and subtracting the base content from the acid content to determine a potential renal acid load (“PRAL”) value. The present disclosure also provides computer implemented processes for predicting PRAL values.
Type:
Application
Filed:
December 21, 2010
Publication date:
May 23, 2013
Applicant:
NESTEC S.A.
Inventors:
Kevin Burke Miller, Zamzam Kabiry Roughead, Jennifer Rae Mager, Douglas Richard Bolster, Norman Alan Greenberg
Abstract: Described herein is the synthesis of adhesive complex coacervates from electrostatically associated block copolymers, wherein the block copolymers comprise alternating polycationic and polyanionic blocks. Methods for making and the using the adhesive complex coacervates are also described herein.
Abstract: The invention relates to a composition for injectable cement, comprising a mineral sold phase, a separate liquid phase and, optionally, microparticles of a biocompatible and biodegradable polymer. The mineral solid phase comprises a mixture of powders with the molar composition: (CP)6 (CaO)y (SrCO3)z, [CP being CaHPO42H2O, CaHPO4, Ca1-xSrxHPO4, an equimolar mixture of bis(Ca(H2PO4)2, H2O and CaO, or a mixture of two or three of said compounds] and y+z=4?1. The liquid phase comprises pure apyrogeneic water or a saline aqueous solution with pH 4 to 9. The ratio L/P [volume of liquid phase/mass of solid mineral phase] is at least 0.4 ml/g. The above is of application as bone replacement.
Type:
Grant
Filed:
April 29, 2005
Date of Patent:
May 14, 2013
Assignees:
Centre National de la Recherche Scientifique, Universite de Montpellier 1
Inventors:
Philippe Boudeville, Michel Vert, Sylvie Munier
Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
Type:
Grant
Filed:
June 16, 2010
Date of Patent:
April 30, 2013
Assignee:
Takeda Vaccines (Montana), Inc.
Inventors:
Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William T. Tino
Abstract: Provided is a method that enables a calcium silicate-based material to be produced more efficiently. The method of producing a calcium silicate-based material comprises: (1) a step of obtaining a reaction product by reacting raw materials containing a calcium component, a silicon component and an aluminum component in an aqueous medium; and (2) a step of forming calcium silicate by subjecting the reaction product to hydrothermal treatment.
Abstract: The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.
Abstract: The present invention relates to compositions, kits and methods for the administration of compositions and kits for supplementation with twelve carbon chain fatty acids or twelve carbon chain acylglycerols; and specifically for the supplementation with twelve carbon chain fatty acids such as lauric acid and twelve carbon chain acylglycerols such as monolaurin; and specifically for the co-supplementation with other vitamins, minerals and nutrients.
Type:
Application
Filed:
September 29, 2011
Publication date:
April 4, 2013
Inventors:
Philippe PERRIN, Guillaume HERRY, Cecile BOYER-JOUBERT
Abstract: A process for producing a biocompatible material includes the steps of mixing an extract of a fish scale-derived hydroxyapatite (with water content of 70 to 75% by weight) and of a fish scale-derived collagen (with water content of 40 to 60% by weight) in the weight percent ratio of about 8:2, stirring the mixture and drying the mixture by a hot blast in order to obtain a composite.
Abstract: Provided is a formulation for oral teeth, which includes a plurality of calcium ion carriers and a plurality of calcium-containing particulates. The particulates are carried by the calcium ion carriers, such that the formulation can prevent or rapidly treat dentin-associated symptoms or diseases, while providing a prolonged prophylactic or therapeutic effect.
Abstract: A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin E, and the vasodilator comprising magnesium provides an additive effect that is equal to or greater than a sum of the effects of the individual components.
Type:
Application
Filed:
November 16, 2012
Publication date:
March 28, 2013
Applicant:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor:
The Regents of the University of Michigan
Abstract: A cause and cure for Rheumatiod Arthritis which includes the body becoming acid and retaining fluids as a means of diluting said acid. Calcium with adequate vitamin D for absorption neutralizes said acid and brings the body back in balance. In addition, an overabundance of the mineral potassium slows the removal of fluid from the body causing fluid to be retained and stored in the joints and soft tissues. Said storage of retained fluid is what causes the symptoms of rheumatoid arthritis and related illnesses and even fibromyalgia and headaches. Joints become swollen and prolonged inflammation results in joint deformity. Said abundance of potassium also causes an imbalance of other minerals in the body, especially sodium, resulting in dehydration. Water and balanced electrolytes must be added to correct the problem.
Abstract: The invention relates to a metallic effect pigment selected from platelet-shaped aluminum, platelet-shaped metallic pigments having a copper fraction of 60% to 100% by weight, and mixtures thereof, having a coating of silicon oxide SiOx, where x is a number from 1 to 2, where the coated metallic effect pigment comprises metal cations and phosphorus- and/or sulfur-containing anions present independently of one another on the metallic effect pigment surface and/or in the silicon oxide layer SiOx, and the element ratio in atomic fractions of metal cation MC and phosphorus P and/or sulfur S to silicon Si is defined by formulae (I) and (II): 100%×(MC+P)/Si??(I) and/or 100%×(MC+S)/Si??(II) and being in total in a range from 0.5% to 35%. The invention further relates to the coated metallic effect pigments producible via the method of the invention, and to the use thereof.
Abstract: The present invention relates to wound care products, devices and methods incorporating acetic acid for the treatment of bacterial infections, in particular bacterial biofilm infections. In particular it relates to a wound care product comprising acetic acid, wherein the product comprises at least one further antibacterial compound; a delivery system comprising a container connected to a means of delivery which is connected to a pad, wherein said container comprises a composition comprising acetic acid and said pad comprises a self-adhesive material; a kit comprising a dressing and an adhesive membrane, wherein the dressing comprises a composition comprising acetic acid; a method of treating a wound comprising a) applying acetic acid to the wound and b) applying a negative pressure to the wound.
Type:
Application
Filed:
December 21, 2010
Publication date:
March 7, 2013
Applicants:
RIGSHOSPITALET, COPENHAGEN UNIVERSITY HOSPITAL, BISPEBJERG HOSPITAL, DANMARKS TEKNISKE UNIVERSITET
Inventors:
Michael Christian Givskov, Thomas Bjarnsholt, Klaus Kirketerp-Møller
Abstract: This invention is a topical treatment for the skin, used for skin enhancement, firming, smoothing, refining and to reduce the appearance of cellulite; that has a self-warming or thermogenic effect comprised of a base combination of warming herbs (Ayurvedic), being any herbs that create a warming effect, combined with dietary minerals that can be blended together in any ratio.
Abstract: An item of clothing (10) for daily pharmacological treatment of a fungal infection, comprising: a textile material (20) to manage moisture when the item of clothing (10) is worn; microcapsules (30) grafted on the textile material (20); and antifungal agents encapsulated within the microcapsules (30) to pharmacologically treat the fungal infection when released from the microcapsules (30).
Type:
Application
Filed:
August 26, 2011
Publication date:
February 28, 2013
Inventors:
Marcus Chun Wah YUEN, Joanne Yiu Wan YIP, Kevin CHEUK, Chi Wai KAN, Shuk Yan CHENG
Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
Type:
Application
Filed:
September 1, 2010
Publication date:
February 28, 2013
Applicant:
Nestec S.A.
Inventors:
Douglas Richard Bolster, Zamzam Kabiry Roughead
Abstract: This disclosure relates to methods of treating or preventing cancer comprising administering a pharmaceutical composition comprising noscapine or noscapine derivatives to a subject diagnosed with a mutated adenomatous polyposis coli (APC) gene.
Abstract: The present disclosure relates to non-acidic extracts or fractions selected from a Boswellia low polar gum resin extract fraction (BLPRE), a Boswellia volatile oil fraction (BVOIL), and a Boswellia oil fraction (BOIL) and their compositions. BLPRE, BOIL, and BVOIL are each derived from the gum resin of a Boswellia species. These compositions are useful for improving mental condition, enhancing brain functions such as cognition, memory, learning, communication and brain health, for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases. Additionally, BOIL, BVOIL, and mixtures of BOIL and BVOIL are useful for enhancing the bioavailability of a biological agent.
Abstract: The present invention provides compositions that contain magnesium and threonate, or a threonate precursor molecule, formulated for extended or modified release to provide physiological concentrations over a desired time period. The extended release or modified release form is particularly useful in providing Mg to a subject while avoiding adverse side effects such as diarrhea.
Abstract: A method for treating a surface with a therapeutic agent is disclosed. The method comprises precipitating a therapeutic agent from a hydrophilic polymeric base layer with which the therapeutic agent has been complexed, to form a layer comprising microparticles of the therapeutic agent on the hydrophilic polymeric base layer, the hydrophilic polymeric base layer being grafted to the surface. Devices comprising a surface having a hydrophilic polymeric base layer comprising a hydrophilic polymer grafted to the surface and a layer comprising microparticles of a therapeutic agent disposed on and complexed with the hydrophilic polymeric base layer are also disclosed.